FENTANYL
Opioid Use Disorder
Jacques E. ChellySmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Opioid Use Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Jacques E. Chelly | Phase 4 | BBB |
LIDOCAINE Jacques E. Chelly | Phase 4 | BBB |
Tirzepatide T. John Winhusen, PhD | Phase 2 | CCC |
Lacosamide Indiana University | Phase 1 | CC |
Sevoflurane Jacques E. Chelly | Early Phase 1 | C |
betacarotene Yale University | Early Phase 1 | C |
PROPOFOL Jacques E. Chelly | Early Phase 1 | C |
Same molecule, other indications
FENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →